4.6 Review

Early Neonatal Cardiac Phenotype in Hurler Syndrome: Case Report and Literature Review

Journal

GENES
Volume 13, Issue 8, Pages -

Publisher

MDPI
DOI: 10.3390/genes13081293

Keywords

Hurler syndrome; MPS IH; newborn screening; enzyme replacement therapy; hematopoietic stem cell transplant; cardiomyopathy

Funding

  1. University of Minnesota

Ask authors/readers for more resources

Mucopolysaccharidosis type I (MPS I) is a rare lysosomal disorder that affects multiple tissues and organs. This study presents a case of early cardiac manifestation in an MPS I patient, emphasizing the importance of early evaluation and treatment for improved outcomes.
Mucopolysaccharidosis type I (MPS I) is a rare inherited lysosomal disorder caused by deficiency of the alpha-L-iduronidase enzyme, resulting in the progressive accumulation of glycosaminoglycans (GAGs), which interfere with the normal function of multiple tissues and organs. The clinical phenotype includes characteristic facial features, hepatosplenomegaly, dysostosis multiplex, umbilical and inguinal hernias, progressive cognitive deficits with corresponding hydrocephalus, and neuropathology. Untreated children do not survive into the second decade. The common cardiac phenotype seen in MPS I and other MPS types includes valve thickening and dysfunction, conduction abnormalities, coronary artery disease, and cardiomyopathy-usually seen later in the disease course. A 15-month-old ex-35-weeker who presented with cardiomyopathy and left ventricular failure at the age of three weeks is presented here. Early evaluation and diagnosis with the help of newborn screening (NBS), followed by treatment with enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), resulted in improvement of his cardiopulmonary status. In MPS I, an early cardiac phenotype is uncommon. Based on the evidence from the literature review for early neonatal cardiac phenotype, we propose that all infants with abnormal newborn screening for MPS I should receive cardiac screening with echocardiogram and NT-proB-type natriuretic peptide (BNP) during the initial evaluation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available